Abstract
Sodium glucose co-transporter 2 (SGLT2) inhibitors, such as dapagliflozin, have demonstrated favorable effects in patients with type 2 diabetes (T2D). However, there are limited reports in the literature regarding the glucose-lowering effects of SGLT2 inhibitors in actual clinical settings. The post-marketing surveillance data from a longitudinal prospective study of 2007 patients with T2D who were prescribed dapagliflozin (10 mg/day) were analyzed (ClinicalTrials.gov, NCT02252224). After 12 weeks of dapagliflozin treatment, glycated hemoglobin (HbA1c) and body mass index were significantly decreased (P < 0.001) from 8.1 ± 1.3% to 7.5 ± 1.2% and from 28.1 ± 4.4 to 27.6 ± 4.2 kg/m2, respectively. Both body weight and HbA1c were reduced in 67.7% of patients, and HbA1c was lowered in 75.1%. Younger age, male sex, shorter diabetes duration, higher baseline HbA1c and estimated glomerular filtration rate (eGFR), and having dapagliflozin as add-on therapy were associated with stronger HbA1c reductions after dapagliflozin use (all P < 0.05). Moreover, subgroup analysis of eGFR of subjects with renal hyperfiltration (eGFR ≥ 120 ml/min/1.73 m2) showed the largest reduction in glucose level (% change, - 9.5; 95% CI - 6.8 to - 12.3 for HbA...Continue Reading
References
Mar 3, 2007·Kidney International·M TomaszewskiA F Dominiczak
May 6, 2009·Annals of Internal Medicine·Andrew S LeveyUNKNOWN CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
Jun 23, 2009·Diabetes Care·Giacomo ZoppiniEnzo Bonora
Jun 4, 2010·Diabetes, Obesity & Metabolism·L ZhangM Pfister
Jun 23, 2010·Diabetes Care·Ele FerranniniJames F List
Jul 9, 2010·Lancet·Clifford J BaileyJames F List
May 25, 2011·Endocrine Reviews·Muhammad A Abdul-GhaniRalph A Defronzo
Jan 13, 2012·The Journal of Clinical Endocrinology and Metabolism·Jan BolinderShamik Parikh
Feb 22, 2012·Nature Reviews. Nephrology·Imed HelalRobert W Schrier
Mar 15, 2012·International Journal of Clinical Practice·R R HenryJ F List
Mar 27, 2012·Diabetes Care·Julio RosenstockJames F List
Jan 28, 2014·The Journal of Clinical Investigation·Ele FerranniniHans-Juergen Woerle
Mar 15, 2014·Diabetes & Metabolism Journal·Chul Sik KimUNKNOWN Taskforce Team of Diabetes Fact Sheet of the Korean Diabetes Association
Jul 22, 2014·Biopharmaceutics & Drug Disposition·Yukihiro ChinoIkumi Tamai
Sep 13, 2014·Diabetes & Metabolism Journal·Chang Hee JungJoong-Yeol Park
Jan 21, 2015·Diabetes, Obesity & Metabolism·M J DaviesG Meininger
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Oct 20, 2015·Expert Opinion on Pharmacotherapy·Yuta NakamuraYasushi Tanaka
Dec 1, 2015·Diabetes & Metabolism Journal·Eun Hee SimYang Ho Kang
Nov 20, 2016·Medicine·Eugene HanEun Seok Kang
Jan 17, 2017·Diabetes & Metabolism·J-Y LeeE S Kang
Mar 18, 2017·Clinical Journal of the American Society of Nephrology : CJASN·Sergei PetrykivHiddo J L Heerspink
Mar 24, 2017·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·So Ra KimByung-Wan Lee
Apr 4, 2017·Scientific Reports·Negar NaderpoorBarbora de Courten
Apr 28, 2017·Diabetes & Metabolism Journal·Kyung Wan MinBong Soo Cha
Jun 29, 2017·Medicine·Eugene HanBong-Soo Cha
Aug 29, 2017·Diabetes, Obesity & Metabolism·Yumo ZhaoLimeng Chen
Nov 25, 2017·Diabetes, Obesity & Metabolism·Motoshi OuchiNaohiko Anzai
Citations
Sep 14, 2019·Journal of Endocrinological Investigation·G P FadiniUNKNOWN DARWIN-T2D Network
Aug 25, 2019·Advances in Therapy·Yehuda Handelsman
Nov 23, 2018·Expert Opinion on Drug Metabolism & Toxicology·Alvaro Garcia-RoperoCarlos G Santos-Gallego
Mar 17, 2019·Diabetes & Metabolism Journal·A Ram HongMin Kyong Moon
Jun 27, 2019·Drugs·Sohita Dhillon
Jan 23, 2020·Journal of Clinical Medicine·Eugene HanBong-Soo Cha
Nov 27, 2020·PeerJ·Jung-Fu ChenShih-Te Tu
Oct 30, 2020·Diabetes, Obesity & Metabolism·Eun Sil KohHyuk-Sang Kwon
Jul 30, 2021·Current Opinion in Pharmacology·Ilaria CampesiFlavia Franconi